APO-Bortezomib bortezomib 3.5mg powder for injection vial

Land: Australia

Språk: engelsk

Kilde: Department of Health (Therapeutic Goods Administration)

Aktiv ingrediens:

bortezomib, Quantity: 3.5 mg

Tilgjengelig fra:

Arrotex Pharmaceuticals Pty Ltd

INN (International Name):

Bortezomib

Legemiddelform:

Injection, powder for

Sammensetning:

Excipient Ingredients: mannitol

Administreringsrute:

Subcutaneous, Intravenous

Enheter i pakken:

1

Resept typen:

(S4) Prescription Only Medicine

Indikasjoner:

Bortezomib, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,Bortezomib, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,Bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy and who have progressive disease.

Produkt oppsummering:

Visual Identification: White to off-white powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Autorisasjon status:

Licence status A

Autorisasjon dato:

2015-07-22